Sort   by:  
 Page size 
ProteomicsEx vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma
Multiple myeloma (MM) is a plasma cell malignancy defined by complex genetics and extensive patient heterogeneity. Despite a growing arsenal of approved therapies, MM remains incurable and in need of guidelines to identify effective personalized treatments. Here, we survey the ex vivo drug and immun...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2022-03-06 | MSV000088992 | MassIVE
ProteomicsHigh-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity
Glioblastoma, the most aggressive primary brain cancer, has dismal prognosis, yet systemic treatment is limited to DNA-alkylating chemotherapies. New therapeutic strategies may emerge from exploring neurodevelopmental and neurophysiological vulnerabilities of glioblastoma. To this end, we here syste...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
MSV000090357 | MassIVE
Sort   by:  
 Page size